Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 301–400 of 1,139
Sex Differences in Obesity and Its Treatment
Ghanta, A., Wilson, E., & Chao, A. M. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01601-z · Cited by 20
“Among those on the highest dose of retatrutide (12 mg), females lost 26.6% of initial body weight versus males who lost 21.9% [ 83].”
InfluentialGlucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
Richter, M. M., Kemp, I. M., Heebøll, S., Winther‐Sørensen, M., Kjeldsen, S. A. S., Jensen, N. J., Nybing, J. D., Linden, F. H., Høgh‐Schmidt, E., Boesen, M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155915 · Cited by 15
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“In phase 2 for obesity [61 ], retatrutide (1–12 mg) induced dose-dependent weight loss, reaching 24.2% at 48 weeks versus 2.1% with placebo.”
InfluentialCurrent and Future Medications for Obesity Treatment
Kushner, R. F., Jastreboff, A. M., & Ryan, D. H. (2025) · JAMA · doi:10.1001/jama.2025.13665 · Cited by 24
Self-citationEngineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Nowak, K., Łupina, K., Romac, A., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251322002 · Cited by 21
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
“%) in individuals living with obesity after 48 weeks of treatment [94].”
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
“148,150 8 Multiple other enteroendocrine and enteropancreatic multi-agonists are in clinical development.”
Self-citationPhysiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
Zaitoon, H., Wauters, A. D., Rodríguez, L. M., & Lynch, J. L. (2025) · Children · doi:10.3390/children12111427 · Cited by 15
“Triple agonists like retatrutide— targeting GLP-1, GIP, and glucagon receptors—have achieved up to 24.2% weight loss in adults (12-mg group), signaling a new generation of anti-obesity pharmacotherapy [41].”
InfluentialThe effect of bariatric surgery type on cardiac reverse remodelling
Henry, J. A., Abdesselam, I., Deal, O., Lewis, A., Rayner, J. J., Bernard, M., Dutour, A., Gaborit, B., Kober, F., Soghomonian, A., et al. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01474-x · Cited by 19
“Moreover, we showed a correlation between reductions in EAT and reductions in LVei, a marker of pericardial restraint that is increased in people with the obesity phenotype of heart failure with preserved ejection fraction and importantly contributes to hemodynamic congestion [42, 43].”
BackgroundAntidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 15
“A phase 2, double-blind, placebo-controlled RCT demonstrated that retatrutide administration in obese adults for 48 weeks resulted in a significant decrease in body weight and improvement of cardiometabolic parameters, including blood pressure and lipids [67].”
BackgroundWeight Loss Interventions for Adults With Obesity-Related Asthma
Foer, D., Forno, E., Holguín, F., & Cahill, K. N. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.12.041 · Cited by 19
Petersen, J., Merrild, C., Lund, J., Holm, S., & Clemmensen, C. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102027 · Cited by 13
Counting the lifetime cost of obesity: Analysis based on national England data
Heald, A. H., Stedman, M., Fryer, A. A., Davies, M. B., Rutter, M. K., Gibson, M., & Whyte, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15447 · Cited by 16
le Roux, C. W., & Mondoh, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2311731 · Cited by 16
“For the first time, a trial showed that all participants taking either 8 mg or 12 mg retatrutide lost at least 5% or more of their body weight, while the overall safety and tolerability profile were similar to other GLP-1 receptor agonists [20].”
ResultTakrori, E., Peshin, S., & Singal, S. (2025) · Medicina · doi:10.3390/medicina61111987 · Cited by 13
“ALT elevations >3 times the upper limit of normal occurred in 1%, resolving spontaneously; one case of acute pancreatitis was reported [4].”
InfluentialMoon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
“Triple agonists extend this concept further, incorporating an additional component, such as glucagon receptor agonism 81 .”
BackgroundDeng, B., Ruan, T., Lu, W., Ying, J., Li, S., Zhou, R., & Mu, D. (2024) · Endocrine · doi:10.1007/s12020-024-03857-6 · Cited by 19
“And its safety pro fi le is consistent with that of both GLP-1 receptor agonists and dual GIP and GLP-1 receptor agonists [43, 45].”
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
Marathe, S. J., Grey, E. W., Bohm, M. S., Joseph, S. C., Ramesh, A. V., Cottam, M. A., Idrees, K., Wellen, K. E., Hasty, A. H., Rathmell, J. C., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00054-5 · Cited by 19
“In obese patients, SEMA induced a 16% reduction in weight while RETA demonstrated substantial weight loss up to 24% 19,20 .”
Patoulias, D., Koufakis, T., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s471476 · Cited by 19
Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
John, S., Bhowmick, K., Park, A., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15
Islet hormones at the intersection of glucose and amino acid metabolism
White, P. J., Albrechtsen, N. J. W., & Campbell, J. E. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01100-4 · Cited by 18
“The transition from developing GCGR antagonists for treating T2DM to focusing on glucagon agonism highlights this progress, with current clinical trials demonstrating promising effects on glucose control and body weight 5 .”
Crosstalk between alcohol use disorder and obesity: two sides of the same coin?
Leggio, L., Farokhnia, M., Kenny, P. J., Pepino, M. Y., & Simmons, W. K. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03259-8 · Cited by 18
“…to the fi rst generation of GLP-1RAs (e.g., exenatide), newer GLP-1RAs (e.g., semaglutide) and poly agonists (e.g., tirzepatide, retatrutide) have higher af fi nity for the GLP-1R, longer half-lives, and are more potent, leading to high ef fi cacy for glucose control and weight reduction [201 – 203].”
Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease
Gu, C., Bernstein, N., Mittal, N., Kurnool, S., Schwartz, H. R., Loomba, R. S., & Malhotra, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082231 · Cited by 16
“The Triple-Hormone-Receptor Agonist Retatrutide for Obesity was a phase 2 trial which examined retatrutide at various doses and dose-escalation regimens in patients with obesity [60].”
BackgroundWong, S. W., Yang, Y., Chen, H., Xie, L. H., Shen, X., Zhang, N., & Wu, J. H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01466-7 · Cited by 14
“Of note, retatrutide exerted a positive dose-dependent effect on the heart rate, peaking at week 24, and subsequently declining [51].”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“In a phase 2 RCT, weekly doses of 12 mg of retatrutide induced over 24% WL in adults with obesity [148].”
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
Khani, M., Afsahi, R., Nasab, A. E., Bi’aragh, S. H., Rasouli, K., Ahangar, M. H., Soltani, A., & Pourahmad, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01925-z · Cited by 23
Effects of weight-loss interventions on bone health in people living with obesity
Paccou, J., Gagnon, C., Yu, E. W.-Y., & Rosen, C. J. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf135 · Cited by 18
Guy, A., Azab, A. N., Liberty, I. F., Afawi, Z., Alhoashla, A., & Abu Tailakh, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15436 · Cited by 12
“33 Another drug is orforglipron, which is administered orally and may lead to improved outcomes given its ease of administration.”
BackgroundOXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
Melander, S. A., Kayed, A., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176215 · Cited by 11
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 14
Ahmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
“…282 17.0% Lingvay et al [18] Tirzepatide Placebo 73 121 60.3% 6 112 5.4% Mok et al [27] Liraglutide Placebo 23 32 71.9% 3 34 8.8% Jastreboff et al [28] Retatrutide Placebo 63 68 92.6% 18 68 26.5% Rosenstock et al [20] Retatrutide Placebo 2 21 9.5% 1 34 2.9% Elkind-Hirsch et al [19] Liraglutide…”
InfluentialObesity and climate change: co-crises with common solutions
Behrens, P., Champagne, C. M., Halford, J. C. G., Moodie, M., Proietto, J., Rutter, G. A., Samaras, K., & Holly, J. M. P. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1613595 · Cited by 14
Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis
Poljo, A., Reichl, J. J., Bürgi, S., Dirnberger, A. S., Schneider, R., Klasen, J. M., Billeter, A. T., Müller-Stich, B. P., Peterli, R., & Kraljević, M. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08136-5 · Cited by 16
“However, dual-receptor agonists like tirzepatide, and triple-receptor agonists such as retatrutide, have shown greater weight loss potential [39, 40].”
Lambert, G. W., Patel, M., & Lambert, É. (2025) · Metabolites · doi:10.3390/metabo15050286 · Cited by 15
“The recent demonstration of the effectiveness of tirzepatide [118] and retatrutide [119] holds promise for combination therapy targeting GLP-1, GIP, and glucagon to promote weight loss and reduce obesity-related co-morbidities.”
Review on obesity management: diet, exercise and pharmacotherapy
Peri, K., & Eisenberg, M. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000246 · Cited by 13
“61 This weight reduction exceeds that of orforglipron, semaglutide and tirzepatide.”
InfluentialPharmacological therapies for type 2 diabetes: future approaches
Bailey, C. J. (2025) · Diabetologia · doi:10.1007/s00125-025-06581-6 · Cited by 28
Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25112 · Cited by 13
Abdallah, H., Klink, W. H., Derienne, J., Voican, C. S., Perlemuter, G., Courie, R., Dagher, I., & Tranchart, H. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08210-y · Cited by 18
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Pack, A. I., Grunstein, R. R., Mokhlesi, B., Ryan, S., Schwab, R., & Gozal, D. (2025) · SLEEP · doi:10.1093/sleep/zsaf045 · Cited by 14
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
“Notably, the phase 2 trial of retatrutide, a novel triple GIP/GLP-1/glucagon receptor agonist, showed substantial efficacy, with the 12 mg dose achieving − 24.2% ( − 23.6 kg) at 48 weeks compared to − 2.1% ( − 2.1 kg) with a placebo ( p < 0.001, 95% CI: − 26.1 to − 22.3) [34].”
InfluentialManagement of type 2 diabetes in the new era
Liakos, A., Karagiannis, T., Avgerinos, I., Malandris, K., Τσάπας, Α., & Bekiari, E. (2023) · HORMONES · doi:10.1007/s42000-023-00488-w · Cited by 13
Central nervous system pathways targeted by amylin in the regulation of food intake
Hankir, M. K., & Foll, C. L. (2024) · Biochimie · doi:10.1016/j.biochi.2024.10.012 · Cited by 14
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Beetz, N., Kalsch, B., Forst, T. M., Schmid, B., Schultz, A., & Hennige, A. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15984 · Cited by 12
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
Retatrutide: A Triple Incretin Receptor Agonist for Obesity Management
Ray, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276754 · Cited by 11
“Recently, retatrutide, a triple agonist of GLP-1-GIP-GCG receptor, showed positive results for obesity management in a phase-2 trial [11].”
BackgroundA Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 14
Harrington, J., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Lingvay, I., Pagidipati, N. J., Sattar, N. A., Spall, H. G. C. V., Verma, S., & McGuire, D. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02016-z · Cited by 12
“Retatrutide leverages all three previously described mechanisms of weight loss, acting via GLP-1R, GIP, and GCGR agonism [78].”
le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., Hussain, S. A., & Hennige, A. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16167 · Cited by 12
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Yan, K., Yu, H., & Blaise, B. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02534-y · Cited by 20
Stumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Antagonizing GIPR adds fire to the GLP-1R flame
Novikoff, A., & Müller, T. D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.016 · Cited by 12
Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists
Feng, J., & Jin, T. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0026 · Cited by 16
“[76] Several clinical trials on additional GLP-1-based agents including triple agonists (Retatrutide), [77] oral formation (Orforglipron), [78] and combination therapy ( CagriSema) are in the late phase of trials.”
Body weight regulation models in humans: insights for testing their validity
Fernández‐Verdejo, R., Ravussin, É., & Galgani, J. E. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01149-1 · Cited by 11
“Indeed, weight loss induced by anti-obesity drugs shows a greater effect in women than in men 189,190 .”
Concepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., Yovera, J. G. G., Ruvalcaba-Barbosa, G. Y., Cura-Rodríguez, L. D., González-Rodríguez, J. S., Urteaga, L. A. C., Pérez-Reyes, A. I., Aldave, J. E. Q., & Paz‐Ibarra, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.111435 · Cited by 17
Characterization of LY3324954 a long-acting glucagon-receptor agonist
Roell, W. C., Coşkun, T., Kim, T., O’Farrell, L. S., Martin, J. A., Nason, S. R., Hernandez-Alamillo, J., Dhantu, S., Drucker, D. J., Sloop, K. W., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102073 · Cited by 12
“Collectively these studies provide deeper mechanistic understanding to the bene fi ts observed in GCGR-based coagonists [23 e 25,27,42].”
Self-citationCzernichow, S., Rassy, N., Carette, C., Shoung, N., Hu, F. B., & Rives‐Lange, C. (2025) · Obesity Reviews · doi:10.1111/obr.13890 · Cited by 11
Zhang, S., Yu, B., Xu, J., Jin, S., Li, Y., Bing, H., Li, J., Ma, X., Zhang, X., & Zhao, L. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0533 · Cited by 10
Targeting obesity for therapeutic intervention in heart failure patients
Sato, R., & von Haehling, S. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2363395 · Cited by 10
“Similarly, in another phase 2 trial in non-diabetic overweight and obese subjects, retatrutide reduced body weight in a dose-dependent manner, with a 12 mg once-weekly subcutaneous administration showing a 24.2% weight loss after 48 weeks [156].”
BackgroundInfluentialTreatable Traits-Based Pharmacologic Treatment of Sleep Apnea
Lisik, D., & Zou, D. (2024) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2024.10.002 · Cited by 12
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“%) at the highest 12 mg dose [154].”
Mainieri, F., Bella, S. L., Rinaldi, M., & Chiarelli, F. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05427-4 · Cited by 15
GLP-1R in diabetes mellitus: from basic discovery to therapeutics development
Li, S., Huang, N., Wang, M., Huang, W., Luo, Y., & Huang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610512 · Cited by 21
Habel, N., Infeld, M. M., Lustgarten, D. L., & Meyer, M. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.064 · Cited by 16
Wong, S., Le, G. H., Dri, C. E., Teopiz, K. M., & McIntyre, R. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16660 · Cited by 17
“30 When beta cells were knocked out for Arrb1 , insulin secretion was elevated compared to control islets, which was abrogated by 1 μ M exendin-9.”
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
McGlone, E. R., & Tan, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171219 · Cited by 11
Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
Ahn, Y. J., Maya, J., & Singhal, V. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00566-z · Cited by 12
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
Himmerich, H., & McElroy, S. L. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001869 · Cited by 12
Park, M. Y., Tu, C., Pèrié, L., Verma, N., Serdan, T. D. A., Shamsi, F., Shapses, S. A., Heffron, S. P., Gamallo‐Lana, B., Mar, A. C., et al. (2024) · Endocrinology · doi:10.1210/endocr/bqae141 · Cited by 11
Ruocco, C., Malavazos, A. E., Ragni, M., Carruba, M. O., Valerio, A., Iacobellis, G., & Nisoli, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106892 · Cited by 10
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Zhou, Y., Tu, L., Wang, X., Xu, J., Xu, S., Ning, X., Xiong, X., & Zheng, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01399 · Cited by 10
Adiposity and cancer: systematic review and meta-analysisPreprint
Watts, E. L., Gonzalez-Feliciano, A., Gunter, M. J., Chatterjee, N., & Moore, S. C. (2024) · medRxiv · doi:10.1101/2024.02.16.24302944 · Cited by 13
“These drugs are a new class of promising non-surgical interventions, with randomised controlled trials reporting substantial weight loss (up to 24% reduction in body weight in 48 weeks) 193 .”
BackgroundDiabetocardiology: a new subspecialty?
Braunwald, E. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad541 · Cited by 11
Testosterone Therapy in Older Men: Present and Future Considerations
Yeap, B. B., Tran, C., Douglass, C. M., & McNeil, J. J. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01209-1 · Cited by 11
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque, L. I., Yau, K., & Cherney, D. Z. I. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001066 · Cited by 12
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial
Bhattachar, S., Tham, L. S., Yan, L., Chua, L., Ng, S., Tang, Y., Ibriga, H., Ni, W., Gurbuz, S., Mather, K. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70040 · Cited by 15
“31 The efficacy, safety, and tolerability findings from our 20-week trial support further clinical development of mazdutide as a potential treat-ment for long-term weight loss in people living with overweight or obesity.”
Self-citationIncretin-Based Therapies and Cancer: What’s New?
Medenica, S., Bogdanović, J. M., Vekić, J., Vojinović, T., Babić, I., Bogdanovic, L. M., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Medicina · doi:10.3390/medicina61040678 · Cited by 13
“Importantly, these studies did not identify cases of medullary thyroid cancer or C cell hyperplasia [74,75].”
Clinical and Therapeutic Implications of Male Obesity
Lenart-Lipińska, M., Łuniewski, M., Szydełko, J., & Matyjaszek‐Matuszek, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165354 · Cited by 14
“The drug’s efficacy was similar to that of bariatric-metabolic surgery and the majority of participants receiving the 12-mg dose had lost 20% or more of their baseline weight at 48 weeks and 26% had lost 30% or more of their original weight [105].”
Novel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF
Doiron, J. E., Elbatreek, M. H., Xia, H., Yu, X., Gehred, N., Gromova, T., Chen, J., Driver, I. H., Muraoka, N., Jensen, M. B., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.011 · Cited by 12
Wen, Y., Lemen, D., Lin, Y., Chen, Y., Regmi, A., Roell, W. C., Thomas, M. K., Hartman, M. L., Coşkun, T., Miličević, Z., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16661 · Cited by 11
“21,22 Retatrutide differentiates itself from previous incretin agonists through its agonism on the glucagon receptor (GCGR).”
InfluentialSelf-citationde Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.019 · Cited by 12
Does Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“Among users of the highest dose, 48% of participants achieved a weight reduction exceeding 25% of their baseline weight, with 26% losing more than 30% [110].”
Brown, A., Mellor, D., Makaronidis, J., Shuttlewood, E., Miras, A. D., & Pournaras, D. J. (2024) · Nutrition Bulletin · doi:10.1111/nbu.12700 · Cited by 9
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
“Investigations to date have demonstrated promising safety and efficacy profiles [178].”
How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?
Gou, Y., & Schwartz, M. W. (2023) · Journal of Clinical Investigation · doi:10.1172/jci174597 · Cited by 9
“Earlier this year, the New England Journal of Medicine published the results of a phase II trial of a triple hormone agonist (Retatrutide), a long-acting drug that combines a potent glucagon receptor agonist with agonists of both GLP-1 and GIP receptors into a single molecule (2).”
BackgroundThe Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Tonin, G., Eržen, S., Mlinarič, Z., Jurišić‐Eržen, D., Horvat, S., Kunej, T., & Klen, J. (2025) · Obesity Reviews · doi:10.1111/obr.13978 · Cited by 17
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 12
Singh, A., & Nissen, S. E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0122 · Cited by 11
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.